Serum anti-Müllerian hormone (AMH) levels correlate with infrarenal aortic diameter in healthy older men: is AMH a cardiovascular hormone?

Dennis, Nicola A.; Jones, Gregory T.; Chong, Yih Harng; Rij, André M. van; McLennan, Ian S.

doi:10.1530/joe-13-0125

Cited by 33 publications

(39 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dennis et al introduced AMH as a novel regulator of the cardiovascular system and declared that serum AMH levels in healthy older men inversely correlate with the diameter of their abdominal aorta [9]. In this regard, related animal studies on AMH association with atherosclerosis are available for rhesus monkeys [44].…”

Section: Discussionmentioning

confidence: 99%

“…An applicable implication of our observations is that AMH nomograms in men might provide information regarding different health statuses. Although, data is limited in this regard, recent evidence states that AMH is no longer a mere reproductive hormone and perhaps has regulatory effects in diseases like lung cancer[46] or as above mentioned in cardiovascular disorders [9]. …”

Section: Discussionmentioning

confidence: 99%

“…Specifically, the role of AMH in the diagnosis of boy's hypogonadism[4], anorchia[5], cryptorchidism[6] and disorders of sex development[7]has been previously confirmed. Besides evaluating the gonadal function, there exist reports indicating AMH as a predictor of renal[8] or cardiovascular diseases in middle-aged or older men[9]; suggesting new insights from a clinical standpoint. However, the pattern of AMH secretion varies greatly among different age groups and also between the elderly men of similar age [10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum variations of anti-mullerian hormone and total testosterone with aging in healthy adult Iranian men: A population-based study

et al. 2017

View full text Add to dashboard Cite

BackgroundLiterature proves anti-mullerian hormone (AMH) and total testosterone (TT) as two important reproductive hormones in male development, however evidence regarding age variations of these hormones is lacking.AimsTo estimate the normal serum AMH values and to assess the age-specific TT levels in men aged 30–70, we conducted the present population-based study.MethodsA total of 831 healthy eligible men, aged 30–70 years, were recruited from Tehran Lipid and Glucose study cohort. Centiles for AMH were estimated according to the exponential normal 3-parameter model. The parametric method of Royston available in general software was applied for the first time to estimate the age-specific AMH and TT percentiles of 5th, 10th, 25th, 50th, 75th, 90th and 95th.ResultsMean AMH level was 6.93, ranging from 0.1 to 40.1 ng/ml. Serum AMH concentrations followed a steady reduction with increasing age. Mean TT level was 4.8, ranging from 0.44 to 11.4 ng/ml.DiscussionA measurable serum concentrations of AMH in healthy males throughout lifespan with variations, based on age, confirming a slight age-related AMH decline. Fractional polynomial (FP) regression models revealed that the mean and standard deviation (SD) of the TT were not associated with age, so the percentiles estimated were not age-specific.ConclusionWe presented a nomogram of age-specific AMH values in a healthy cohort of Iranian men. This finding might have clinical importance in dealing hormonal disorders in men.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum variations of anti-mullerian hormone and total testosterone with aging in healthy adult Iranian men: A population-based study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In particular, recent experimental and observational studies have identified AMH as a potential influencing factor of cardiovascular function or risk factors of CVD. [14][15][16][17][18] To date, no studies have investigated a direct link between AMH and clinical CVD occurrence. Therefore, in this study, we aimed to determine whether an independent relationship exists between longitudinal trajectories of AMH and clinically manifest CVD in women from the general population.…”

mentioning

confidence: 99%

Anti-Müllerian Hormone Trajectories Are Associated With Cardiovascular Disease in Women

et al. 2017

View full text Add to dashboard Cite

BACKGROUND:Earlier age at menopause is widely considered to be associated with an increased risk of cardiovascular disease. However, the underlying mechanisms of this relationship remain undetermined. Indications suggest that anti-Müllerian hormone (AMH), an ovarian reserve marker, plays a physiological role outside of the reproductive system. Therefore, we investigated whether longitudinal AMH decline trajectories are associated with an increased risk of cardiovascular disease (CVD) occurrence. METHODS:This study included 3108 female participants between 20 and 60 years of age at baseline of the population-based Doetinchem Cohort. Participants completed ≥1 of 5 consecutive quinquennial visits between 1987 and 2010, resulting in a total follow-up time of 20 years. AMH was measured in 8507 stored plasma samples. Information on total CVD, stroke, and coronary heart disease was obtained through a hospital discharge registry linkage. The association of AMH trajectories with CVD was quantified with joint modeling, with adjustment for age, smoking, oral contraceptive use, body mass index, menopausal status, postmenopausal hormone therapy use, diastolic blood pressure, total cholesterol, highdensity lipoprotein cholesterol, and glucose levels. RESULTS:By the end of follow-up, 8.2% of the women had suffered from CVD, 4.9% had suffered from coronary heart disease, and 2.6% had experienced a stroke. After adjustment, each ng/mL lower log AMH level was associated with a 21% higher risk of CVD (hazard ratio, 1.21; 95% confidence interval, 1.07-1.36) and a 26% higher risk of coronary heart disease (hazard ratio, 1.25; 95% confidence interval, 1.08-1.46). Each additional ng/mL/year decrease of log AMH was associated with a significantly higher risk of CVD (hazard ratio, 1.46; 95% confidence interval, 1.14-1.87) and coronary heart disease (hazard ratio, 1.56; 95% confidence interval, 1.15-2.12). No association between AMH and stroke was found. CONCLUSIONS:These results indicate that AMH trajectories in women are independently associated with CVD risk. Therefore, we postulate that the decline of circulating AMH levels may be part of the pathophysiology of the increased cardiovascular risk of earlier menopause. Confirmation of this association and elucidation of its underlying mechanisms are needed to place these results in a clinical perspective.

show abstract

“…Men with enlarged aortic diameter are also reported to have lower AMH levels [8]. In contrast men, free of arterial cardiovascular disease had higher AMH levels which were similar to levels of AMH in younger men [4].…”

Section: Introductionmentioning

confidence: 80%

Relationships between Anti-mullerian Hormone, Testosterone, Luteinizing Hormone and Follicle Stimulating Hormone in Men on Testosterone Therapy

Hadlow¹,

Hamilton²,

Joseph³

et al. 2017

Clin Med Biochemistry

View full text Add to dashboard Cite

Aim: To assess if testosterone therapy, with suppression of LH and FSH altered AMH levels in men. Study background:AMH is an important male hormone and is increasingly measured by laboratories for men and women's health assessments. This prospective study was conducted in community medical centres to assess the effects of testosterone on AMH levels in men.Methods: Men (n=15) with androgen deficiency symptoms, who were prescribed a trial of testosterone therapy by their own practitioner for at least 6 months, consented to participate in a study measuring AMH pre-therapy and post-therapy. Testosterone therapy was given to achieve LH and FSH suppression. Measurement of testosterone, LH, FSH and AMH at baseline and post testosterone therapy on at least 2 occasions including at 6 months was completed in all men. Men with abnormal baseline biochemistry (elevated LH or testosterone below age appropriate ranges) were excluded (n=5) from further study. Results:In the study group baseline LH was normal (<8 U/L) and baseline testosterone was 7-23 (mean 12 nmol/L) and within age specific intervals. Mean baseline AMH was 36 pmol/L (range 19-89) and within age related intervals. A significant rise (p=0.001) of at least 1.5-fold in testosterone occurred post treatment (range 1.5-7.5-fold increase) with suppression of LH to <1 U/L with therapy. AMH showed variable changes after testosterone. There was no significant trend in AMH either rising or falling compared to baseline and levels were not associated with testosterone (p=0.197) nor affected by the suppression of FSH or LH (p=0.683, 0.271 respectively). Conclusions:No significant pattern of change occurs in AMH in adult men at 6 months undergoing exogenous testosterone therapy. Laboratories do not need to adjust AMH reference intervals for effects of testosterone therapy in men with normal baseline LH and testosterone prior to therapy.

show abstract

Serum anti-Müllerian hormone (AMH) levels correlate with infrarenal aortic diameter in healthy older men: is AMH a cardiovascular hormone?

Cited by 33 publications

References 31 publications

Serum variations of anti-mullerian hormone and total testosterone with aging in healthy adult Iranian men: A population-based study

Serum variations of anti-mullerian hormone and total testosterone with aging in healthy adult Iranian men: A population-based study

Anti-Müllerian Hormone Trajectories Are Associated With Cardiovascular Disease in Women

Relationships between Anti-mullerian Hormone, Testosterone, Luteinizing Hormone and Follicle Stimulating Hormone in Men on Testosterone Therapy

Contact Info

Product

Resources

About